Biomarker-directed therapy of squamous carcinomas of the head and neck: targeting PI3K/PTEN/mTOR pathway.
作者信息
Holsinger Floyd Christopher, Piha-Paul Sarina Anne, Janku Filip, Hong David S, Atkins Johnique T, Tsimberidou Apostolia M, Kurzrock Razelle
机构信息
University of Texas MD Anderson Cancer Center, Houston, TX, USA.
出版信息
J Clin Oncol. 2013 Mar 20;31(9):e137-40. doi: 10.1200/JCO.2012.43.2716. Epub 2013 Jan 28.
Abstract
摘要
相似文献
1
Biomarker-directed therapy of squamous carcinomas of the head and neck: targeting PI3K/PTEN/mTOR pathway.生物标志物导向的头颈部鳞状细胞癌治疗：靶向PI3K/PTEN/mTOR通路
J Clin Oncol. 2013 Mar 20;31(9):e137-40. doi: 10.1200/JCO.2012.43.2716. Epub 2013 Jan 28.
2
A comprehensive evaluation of biomarkers predictive of response to PI3K inhibitors and of resistance mechanisms in head and neck squamous cell carcinoma.对头颈部鳞状细胞癌中预测PI3K抑制剂反应的生物标志物及耐药机制的综合评估。
Mol Cancer Ther. 2014 Nov;13(11):2738-50. doi: 10.1158/1535-7163.MCT-13-1090. Epub 2014 Sep 5.
3
Phase II clinical and exploratory biomarker study of dacomitinib in patients with recurrent and/or metastatic squamous cell carcinoma of head and neck.达克替尼治疗复发性和/或转移性头颈部鳞状细胞癌的 II 期临床及探索性生物标志物研究。
Clin Cancer Res. 2015 Feb 1;21(3):544-52. doi: 10.1158/1078-0432.CCR-14-1756. Epub 2014 Nov 25.
4
Dysregulations in the PI3K pathway and targeted therapies for head and neck squamous cell carcinoma.PI3K通路失调与头颈部鳞状细胞癌的靶向治疗
Oncotarget. 2017 Mar 28;8(13):22203-22217. doi: 10.18632/oncotarget.14729.
5
A phase II study of temsirolimus added to low-dose weekly carboplatin and paclitaxel for patients with recurrent and/or metastatic (R/M) head and neck squamous cell carcinoma (HNSCC).替西罗莫司联合低剂量每周卡铂和紫杉醇治疗复发性和/或转移性（R/M）头颈部鳞状细胞癌（HNSCC）患者的 II 期研究。
Ann Oncol. 2017 Oct 1;28(10):2533-2538. doi: 10.1093/annonc/mdx346.
6
Chemopreventive and chemotherapeutic actions of mTOR inhibitor in genetically defined head and neck squamous cell carcinoma mouse model.mTOR 抑制剂在遗传定义的头颈部鳞状细胞癌小鼠模型中的化学预防和化学治疗作用。
Clin Cancer Res. 2012 Oct 1;18(19):5304-13. doi: 10.1158/1078-0432.CCR-12-1371. Epub 2012 Aug 2.
7
MEK Inhibitor PD-0325901 Overcomes Resistance to PI3K/mTOR Inhibitor PF-5212384 and Potentiates Antitumor Effects in Human Head and Neck Squamous Cell Carcinoma.MEK抑制剂PD-0325901克服对PI3K/mTOR抑制剂PF-5212384的耐药性并增强对人头颈鳞状细胞癌的抗肿瘤作用。
Clin Cancer Res. 2015 Sep 1;21(17):3946-56. doi: 10.1158/1078-0432.CCR-14-3377. Epub 2015 May 14.
8
Phase II trial of everolimus in patients with previously treated recurrent or metastatic head and neck squamous cell carcinoma.依维莫司用于既往接受过治疗的复发性或转移性头颈部鳞状细胞癌患者的II期试验。
Head Neck. 2016 Dec;38(12):1759-1764. doi: 10.1002/hed.24501. Epub 2016 May 27.
9
Molecular-targeted therapies in the treatment of squamous cell carcinomas of the head and neck.头颈部鳞状细胞癌治疗中的分子靶向疗法
Curr Opin Oncol. 2008 May;20(3):256-63. doi: 10.1097/CCO.0b013e3282f9b575.
10
Exploiting the head and neck cancer oncogenome: widespread PI3K-mTOR pathway alterations and novel molecular targets.挖掘头颈部癌症肿瘤基因组：广泛存在的 PI3K-mTOR 通路改变和新的分子靶点。
Cancer Discov. 2013 Jul;3(7):722-5. doi: 10.1158/2159-8290.CD-13-0239.
引用本文的文献
1
The PTEN Tumor Suppressor Gene in Soft Tissue Sarcoma.软组织肉瘤中的PTEN肿瘤抑制基因
Cancers (Basel). 2019 Aug 14;11(8):1169. doi: 10.3390/cancers11081169.
2
Biomarker driven treatment of head and neck squamous cell cancer.生物标志物驱动的头颈部鳞状细胞癌治疗
Cancers Head Neck. 2017 Aug 29;2:6. doi: 10.1186/s41199-017-0025-1. eCollection 2017.
3
Genomic and transcriptomic profiling expands precision cancer medicine: the WINTHER trial.基因组和转录组谱分析拓展精准肿瘤医学：WINTHER 试验。
Nat Med. 2019 May;25(5):751-758. doi: 10.1038/s41591-019-0424-4. Epub 2019 Apr 22.
4
Phenotypic and Genomic Determinants of Immunotherapy Response Associated with Squamousness.与鳞状细胞相关的免疫治疗反应的表型和基因组决定因素。
Cancer Immunol Res. 2019 Jun;7(6):866-873. doi: 10.1158/2326-6066.CIR-18-0716. Epub 2019 Apr 19.
5
Targeted Therapies and Immune-Checkpoint Inhibition in Head and Neck Squamous Cell Carcinoma: Where Do We Stand Today and Where to Go?头颈部鳞状细胞癌的靶向治疗与免疫检查点抑制：我们如今的现状与未来走向？
Cancers (Basel). 2019 Apr 3;11(4):472. doi: 10.3390/cancers11040472.
6
PTEN loss is associated with resistance to cetuximab in patients with head and neck squamous cell carcinoma.PTEN 缺失与头颈部鳞状细胞癌患者对西妥昔单抗的耐药性相关。
Oral Oncol. 2019 Apr;91:69-78. doi: 10.1016/j.oraloncology.2019.02.026. Epub 2019 Mar 4.
7
A phase II study of temsirolimus added to low-dose weekly carboplatin and paclitaxel for patients with recurrent and/or metastatic (R/M) head and neck squamous cell carcinoma (HNSCC).替西罗莫司联合低剂量每周卡铂和紫杉醇治疗复发性和/或转移性（R/M）头颈部鳞状细胞癌（HNSCC）患者的 II 期研究。
Ann Oncol. 2017 Oct 1;28(10):2533-2538. doi: 10.1093/annonc/mdx346.
8
Predicting clinical benefit from everolimus in patients with advanced solid tumors, the CPCT-03 study.CPCT-03研究：预测依维莫司对晚期实体瘤患者的临床获益情况。
Oncotarget. 2017 Mar 8;8(33):55582-55592. doi: 10.18632/oncotarget.16029. eCollection 2017 Aug 15.
9
Squamousness: Next-generation sequencing reveals shared molecular features across squamous tumor types.鳞状特性：新一代测序揭示了跨鳞状肿瘤类型的共同分子特征。
Cell Cycle. 2015;14(14):2355-61. doi: 10.1080/15384101.2015.1053669. Epub 2015 Jun 1.
10
Next generation sequencing demonstrates association between tumor suppressor gene aberrations and poor outcome in patients with cancer.下一代测序显示肿瘤抑制基因畸变与癌症患者的不良预后之间存在关联。
Cell Cycle. 2015;14(11):1730-7. doi: 10.1080/15384101.2015.1033596.
本文引用的文献
1
PI3K/AKT/mTOR inhibitors in patients with breast and gynecologic malignancies harboring PIK3CA mutations.PI3K/AKT/mTOR 抑制剂在携带有 PIK3CA 突变的乳腺和妇科恶性肿瘤患者中的应用。
J Clin Oncol. 2012 Mar 10;30(8):777-82. doi: 10.1200/JCO.2011.36.1196. Epub 2012 Jan 23.
2
Regulation and function of ribosomal protein S6 kinase (S6K) within mTOR signalling networks.核糖体蛋白 S6 激酶（S6K）在 mTOR 信号网络中的调节和功能。
Biochem J. 2012 Jan 1;441(1):1-21. doi: 10.1042/BJ20110892.
3
Advances in the management of recurrent or metastatic squamous cell carcinoma of the head and neck.复发性或转移性头颈部鳞状细胞癌的治疗进展。
Head Neck. 2013 Mar;35(3):443-53. doi: 10.1002/hed.21910. Epub 2011 Nov 2.
4
Human papillomavirus and rising oropharyngeal cancer incidence in the United States.人乳头瘤病毒与美国口咽癌发病率的上升
J Clin Oncol. 2011 Nov 10;29(32):4294-301. doi: 10.1200/JCO.2011.36.4596. Epub 2011 Oct 3.
5
Salivary duct carcinoma: targeting the phosphatidylinositol 3-kinase pathway by blocking mammalian target of rapamycin with temsirolimus.涎腺导管癌：通过替西罗莫司阻断雷帕霉素靶蛋白来靶向磷脂酰肌醇3激酶途径
J Clin Oncol. 2011 Sep 10;29(26):e727-30. doi: 10.1200/JCO.2011.36.2095. Epub 2011 Aug 15.
6
PIK3CA mutations in patients with advanced cancers treated with PI3K/AKT/mTOR axis inhibitors.PI3K/AKT/mTOR 轴抑制剂治疗的晚期癌症患者中的 PIK3CA 突变。
Mol Cancer Ther. 2011 Mar;10(3):558-65. doi: 10.1158/1535-7163.MCT-10-0994. Epub 2011 Jan 7.
7
Human papillomavirus and survival of patients with oropharyngeal cancer.人乳头瘤病毒与口咽癌患者的生存。
N Engl J Med. 2010 Jul 1;363(1):24-35. doi: 10.1056/NEJMoa0912217. Epub 2010 Jun 7.
8
Genetic dissection of the oncogenic mTOR pathway reveals druggable addiction to translational control via 4EBP-eIF4E.对致癌 mTOR 通路的遗传剖析揭示了通过 4EBP-eIF4E 进行药物成瘾的翻译控制。
Cancer Cell. 2010 Mar 16;17(3):249-61. doi: 10.1016/j.ccr.2010.01.021.
9
Targeting PI3K signalling in cancer: opportunities, challenges and limitations.靶向癌症中的PI3K信号通路：机遇、挑战与局限
Nat Rev Cancer. 2009 Aug;9(8):550-62. doi: 10.1038/nrc2664.
10
Platinum-based chemotherapy plus cetuximab in head and neck cancer.铂类化疗联合西妥昔单抗治疗头颈癌。
N Engl J Med. 2008 Sep 11;359(11):1116-27. doi: 10.1056/NEJMoa0802656.
Zotero 插件